Bio-Techne Corp - Asset Resilience Ratio
Bio-Techne Corp (TECH) has an Asset Resilience Ratio of 0.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Bio-Techne Corp total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Bio-Techne Corp's Asset Resilience Ratio has changed over time. See Bio-Techne Corp shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Bio-Techne Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see TECH company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Bio-Techne Corp maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Bio-Techne Corp Industry Peers by Asset Resilience Ratio
Compare Bio-Techne Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
GlycoMimetics Inc
NASDAQ:GLYC |
Biotechnology | 91585.83% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.10% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 2.34% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
Annual Asset Resilience Ratio for Bio-Techne Corp (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Bio-Techne Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 0.00% | $0.00 | $2.56 Billion | -- |
| 2024-06-30 | 0.04% | $1.07 Million | $2.70 Billion | -0.86pp |
| 2023-06-30 | 0.90% | $23.74 Million | $2.64 Billion | -2.35pp |
| 2022-06-30 | 3.24% | $74.46 Million | $2.29 Billion | +1.81pp |
| 2021-06-30 | 1.43% | $32.46 Million | $2.26 Billion | -4.69pp |
| 2020-06-30 | 6.13% | $124.27 Million | $2.03 Billion | +2.67pp |
| 2019-06-30 | 3.46% | $65.15 Million | $1.88 Billion | -0.29pp |
| 2018-06-30 | 3.75% | $59.76 Million | $1.59 Billion | -0.50pp |
| 2017-06-30 | 4.25% | $66.10 Million | $1.56 Billion | +1.45pp |
| 2016-06-30 | 2.80% | $31.60 Million | $1.13 Billion | -2.51pp |
| 2015-06-30 | 5.30% | $56.39 Million | $1.06 Billion | +0.11pp |
| 2014-06-30 | 5.19% | $44.79 Million | $862.49 Million | -16.55pp |
| 2013-06-30 | 21.74% | $169.15 Million | $778.10 Million | +0.56pp |
| 2012-06-30 | 21.17% | $152.31 Million | $719.32 Million | +10.94pp |
| 2011-06-30 | 10.23% | $63.20 Million | $617.67 Million | +2.54pp |
| 2010-06-30 | 7.69% | $39.89 Million | $518.82 Million | -1.20pp |
| 2009-06-30 | 8.89% | $41.95 Million | $472.00 Million | +1.13pp |
| 2008-06-30 | 7.76% | $39.35 Million | $507.37 Million | +1.32pp |
| 2007-06-30 | 6.44% | $29.29 Million | $454.84 Million | +1.25pp |
| 2006-06-30 | 5.19% | $19.21 Million | $370.51 Million | -0.50pp |
| 2005-06-30 | 5.69% | $16.79 Million | $295.26 Million | -32.84pp |
| 2004-06-30 | 38.53% | $125.39 Million | $325.46 Million | +8.85pp |
| 2003-06-30 | 29.68% | $78.13 Million | $263.28 Million | +0.01pp |
| 2002-06-30 | 29.66% | $70.67 Million | $238.25 Million | -5.51pp |
| 2001-06-30 | 35.17% | $75.80 Million | $215.53 Million | +11.63pp |
| 2000-06-30 | 23.54% | $42.47 Million | $180.41 Million | +10.37pp |
| 1999-06-30 | 13.17% | $16.30 Million | $123.80 Million | -- |
About Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various asp… Read more